Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mauriac

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative GroupP F Conte, J Latreille, L Mauriac, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2006
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)R E Coleman, L Biganzoli, P Canney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancerW Jonat, A Howell, C Blomqvist, et al.
Acta Clinica Belgica. Supplementum|January 1, 1986
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]J Bonneterre, H Coppens, L Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Bonneterre, B Thürlimann, J F Robertson, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal womenI Vergote, J Bonneterre, B Thürlimann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Bulletin Du Cancer|January 1, 1986
[Prognostic significance of isolated local recurrences in breast cancer following mastectomy and axillary node excision. Apropos of 77 recurrences in 2362 patients]A Avril, F Bonichon, M Durand, et al.
Breast Cancer Research and Treatment|May 1, 1988
Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centreL Mauriac, M Durand, J Chauvergne, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative GroupP F Conte, J Latreille, L Mauriac, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2006
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)R E Coleman, L Biganzoli, P Canney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancerW Jonat, A Howell, C Blomqvist, et al.
Acta Clinica Belgica. Supplementum|January 1, 1986
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]J Bonneterre, H Coppens, L Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Bonneterre, B Thürlimann, J F Robertson, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal womenI Vergote, J Bonneterre, B Thürlimann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Bulletin Du Cancer|January 1, 1986
[Prognostic significance of isolated local recurrences in breast cancer following mastectomy and axillary node excision. Apropos of 77 recurrences in 2362 patients]A Avril, F Bonichon, M Durand, et al.
Breast Cancer Research and Treatment|May 1, 1988
Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centreL Mauriac, M Durand, J Chauvergne, et al.
Pageof 9